• search
For Quick Alerts
ALLOW NOTIFICATIONS  
For Daily Alerts

Cipla, Boehringer Ingelheim join hands to co-market 3 oral anti-diabetic drugs in India

By PTI
|

New Delhi, Jun 29: Pharma major Cipla and drug firm Boehringer Ingelheim India on Monday announced partnership to co-market three new oral anti-diabetic drugs in the country.

Cipla, Boehringer Ingelheim join hands to co-market 3 oral anti-diabetic drugs in India

The companies have entered into a partnership for co-marketing three new oral anti-diabetics drugs --- Oboravo (Empagliflozin), Oboravo Met (Empagliflozin+Metformin) and Tiptengio (Empagliflozin+Linagliptin) in India, Cipla and Boehringer Ingelheim India Pvt Ltd said in a statement.

Cipremi: Cipla launches 100 mg antiviral drug to treat severe Covid-19 patient, all you need to know

As per the International Diabetes Federation, India is home to 7.7 crore diabetic adults aged between 20-79 years, ranking second behind China, and is poised to reach 13.42 crore patients by 2045, it added.

    Arvind Kejriwal announces plasma bank in Delhi for Covid patients, seeks donors | Oneindia News

    "Diabetes continues to be a focus area for Cipla and with a strategic partnership with Boehringer Ingelheim coupled with our strong brand building, patient access and reach capabilities, we will be at the forefront of providing holistic diabetes care," Cipla India Business Executive VP & CEO Nikhil Chopra said.

    In a similar vein, Boehringer Ingelheim India MD Sharad Tyagi said: "As a dedicated organization to the field of diabetes, we aim to provide wider access and innovative solutions to the medical fraternity and patients with one of the most comprehensive diabetes portfolios in the country".

    Oboravo is approved for glucose-control in patients with type-2 diabetes. It is also approved for reducing the risk of cardiovascular death, in patients with type-2 diabetes and established cardiovascular disease, it added.

    While Oboravo Met can be given to newly diagnosed patients of type-2 diabetes who have higher baseline HbA1c levels, Tiptengio is the world's first approved combination of an SGLT-2 inhibitor and DPP4 inhibitor, the statement said. Shares of Cipla Ltd were trading at Rs 644.20 per unit on the BSE, up 1.50 per cent over previous close.

    For Daily Alerts
    Get Instant News Updates
    Enable
    x
    Notification Settings X
    Time Settings
    Done
    Clear Notification X
    Do you want to clear all the notifications from your inbox?
    Settings X
    X
    We use cookies to ensure that we give you the best experience on our website. This includes cookies from third party social media websites and ad networks. Such third party cookies may track your use on Oneindia sites for better rendering. Our partners use cookies to ensure we show you advertising that is relevant to you. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on Oneindia website. However, you can change your cookie settings at any time. Learn more